Search
Analyst Thursdays: William Blair Senior Analyst Andy Hsieh talks about his new obesity sector report and the companies he initiated
He discusses what to look for in safety and efficacy, new targets, and his thoughts on the potential role of oral therapies. Plus,...
Mar 6
HSBC's Capital Markets Investment Team talks about getting the most out of your company's cash management
Meet the team at HSBC that helps biopharma CFOs (and from other industries) with their cash/liquidity investing. #sponsored
Mar 3
From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers
He shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.
Feb 24
Paula Brown Stafford, CEO of the global CRO Allucent, discusses how the company is purpose built to partner with mid-to-small sized biopharma companies on their success
She describes what appealed to her about Allucent when she took the CEO job in July of last year, and highlights the company's regulatory...
Feb 13
Welcoming Ryan Flinn as BiotechTV's new 'AI in Biotech' contributor
Ryan is based in the Bay Area, and will will be covering AI news there on the ground and virtually worldwide for BiotechTV.
Feb 12
Oppenheimer's Head of Healthcare Investment Banking shares his take on 2025 and highlights M&A, IPOs, and the ability of companies to raise money this year
Michael Margolis discusses the macro and policy factors that are in play this year, comments on the China factor, and describes how...
Feb 11
Mizuho Senior Biotech Analyst Salim Syed shares his take on 2025 and key catalysts from companies he covers
He discusses BridgeBio, Cytokinetics, Wave, Vaxcyte, Iovance, Unity, and Enliven
Feb 11
Dana-Farber Cancer Institute investigators describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur.
Toni Choueiri and Patrick Ott describe how this peptide-based vaccine was peronalized to dozens of the patient's neoantigens in this this ad
Feb 6
SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings
He talks about todays M&A heavy news and the market reaction to it, and comments on Xenon, Madrigal, Nurix, and Wave.
Jan 13
SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development
He shares his thoughts on Moderna's transition, what policies he would like to see promoted in government, competing with China, and the...
Jan 13
SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks
He discusses news from Biogen and Regeneron, and shares his top picks Xenon, Soleno, and Lexeo.
Jan 13
Jon Norris shares highlights from the 2024 HSBC Venture Healthcare Full-Year Report
He provides a 2024 year-end recap and 2025 outlook DOWNLOAD THE FULL REPORT #Sponsored
Jan 10
Baird biotech analyst Jack Allen recaps ASH and other recent news, and shares his outlook for top names in 2025
Jack Allen discusses data that Arcellx and Vor had at last week's ASH annual meeting, and discusses Mereo, Ultragenyx, Instil Bio, Taysha...
Dec 18, 2024
Dimension's Zavain Dar talks about raising a $500M second fund, and describes the firm's ethos of investing in companies that are highly focused in both life sciences and technology
He discusses the founding of Dimension, and highlights entrepreneurs and portfolio companies that have matched the firm's focused...
Dec 16, 2024
NewYorkBIO CEO Jennifer Hawks Bland discusses their annual event at the New York Stock Exchange and what is on the mind of companies today
Over 600 people registered for the event and took in company presentations and networking on the floor of the NYSE.
Dec 10, 2024
ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual Meeting
He talks modalities and targets, and comments on Arcellx, Galapagos, BeiGene, Nurix, Kura, JNJ, Syndax, AbbVie AstraZeneca, CellCentric,...
Dec 7, 2024
London Healthcare Week: Forbion Managing Partner Sander Slootweg shares his thoughts on the year ahead, the IPO market, M&A environment, areas of interest, and more
Fresh off of raising more than €2 billion for two new funds in October, he gives his take on the biotech markets both in Europe and...
Nov 20, 2024
From Seoul: Kicking off BiotechTV's one week visit to Korea by getting an overview of the growth and current state of biotech in the country from KoreaBIO
KoreaBIO Vice President Seung-Kyou Lee and Director of International & Public Affairs Jurie Hwang describe the enormous growth the sector...
Nov 20, 2024
SITC 2024: Parker Institute for Cancer Immunotherapy CSO John Connolly gives an overview of the latest advances in IO
He discusses the latest in TILs, cell therapy, multispecifics, oncolytic viruses and more.
Nov 9, 2024
BioHouston CEO Ann Tanabe kicks off the 2024 Texas Life Science Forum
From the largest conference for life sciences in Texas each year, she describes the significant growth in infrastructure, startups,...
Nov 7, 2024
.png){kind=logo}
